Related Experiment Video
Updated: Oct 27, 2025
05:53
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
10.4K
Independent Community Pharmacists' Experience in Offering Pharmacogenetic Testing
Susanne B Haga1, Rachel Mills1, Jivan Moaddeb1
1Center for Applied Genomics & Precision Medicine, Durham, NC, 27708, USA.
Pharmacogenomics and Personalized Medicine
|July 22, 2021
Summary
Pharmacists in community pharmacies reported positive experiences delivering pharmacogenetic (PGx) testing. Continued PGx service delivery may be hindered by reimbursement and provider engagement challenges.
Area of Science:
- Pharmacogenomics
- Community Pharmacy Practice
- Personalized Medicine
Background:
- Pharmacogenetic (PGx) testing offers personalized therapeutic guidance.
- Integrating PGx services into community pharmacy practice is an emerging area.
- Understanding pharmacist experiences is crucial for successful implementation.
Purpose of the Study:
- To assess community pharmacist experiences delivering PGx testing.
- To compare PGx testing as a standalone service versus integrated with Medication Therapy Management (MTM).
Main Methods:
- Cluster randomized trial involving independent community pharmacies in North Carolina.
- Pharmacists provided PGx testing either as a standalone service or integrated with MTM.
- Data collected via pre- and post-study surveys and semi-structured interviews.
Main Results:
- Pharmacist knowledge of PGx significantly improved post-study.
- Most pharmacists felt qualified to provide PGx testing.
- Higher utilization of educational resources was observed in the PGx-only arm.
- Key concerns for continued service included lack of reimbursement and time commitment.
Conclusions:
- Community pharmacists had a positive experience delivering PGx testing, with or without MTM integration.
- Pharmacists expressed confidence and interest in continuing PGx services.
- Reimbursement and prescriber engagement are critical factors for sustained PGx service delivery in pharmacies.
Related Concept Videos
01:12Analysis of Population Pharmacokinetic Data
474
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
474
01:24Dosage Regimen: Individualization
29
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
29
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
37
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
37
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
39
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
39